Dow Jones Newswires: Japan’s Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion
The Japanese company said it would pay $40.00 per share of Iveric, which booked net loss of $185.2 million and had $534.7 million in net assets in 2022.
Elderly and disabled patients could miss out on healthcare services unless an extension is passed before the end of the...
Apple gets about half of its revenue directly from iPhone sales. But the product is indirectly responsible for far more...
It may seem surprising that spreads on Boeing bonds have tightened since the strike started, even as investors have been...
Consumer confidence fell in September to a three-month low ahead of a pivotal U.S. election whose outcome could hinge on...
Traders can finally relax a little this week as the calendar for corporate earnings and incoming economic data looks relatively...
“While it has not been my baseline outlook, I cannot rule out the risks that progress on inflation could continue...